ENP-501
Phase 2Small molecule
ENP-501 is one of 7 small molecule programs targeting T-ALL. It is currently in Phase 2.
1
Indications
1
Total Trials
1
Active Trials
6
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
8 competitors in T-ALL
#DrugCompanyPhaseTrials
1Venclexta
AbbViePhase 2
Cytosar
TevaPhase 2
Sarclisa
AAzienda U.S.L. 1 di Massa e Carrara
Phase 2
Homoharringtonine
Ascentage Pharma Group Inc.Phase 2
G-CSF
AArog Pharmaceuticals, Inc.
Phase 2
ENP-501
NN-Fold, LLC
Phase 2
Decitabine With Gemox
SSeoul National University Hospital
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for ENP-501. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- NN-Fold, LLC